Step 5: Effective Drug Treatment of HIV
See also Antiretroviral Therapy, Adherence, and Initiating Treatment
Active Resources: 19
Toolkits
-
6/10/2019
-
5/17/2016 (reviewed: 2/20/2019)
-
2/2/2016
-
4/29/2015
Antiretroviral Guidelines
-
4/16/2019
-
12/7/2018
-
10/25/2018
Image Library
-
2/20/2019 (reviewed: 2/20/2019)
Online and Self-Paced Learning
-
2/5/2019 (reviewed: 2/19/2019)
Self-Study Materials
-
2/28/2018
Online Training
-
10/20/2017
-
8/23/2017
Pocket Guides
-
5/1/2017
Webinar Recordings
-
1/12/2017
-
6/8/2016
Primary Care Guidelines
-
11/9/2015
-
6/22/2012
Charts, Tables & Posters
-
9/4/2015
-
7/1/2015
Archive Resources: 11
Webinar Recordings
-
2/19/2015 (reviewed: 5/8/2019)
Charts, Tables & Posters
-
8/22/2014
-
6/1/2013 (reviewed: 1/11/2017)
Toolkits
-
7/31/2014 (reviewed: 2/12/2018)
Videos
-
7/17/2014
-
9/2/2013
Patient Information
-
7/7/2014 (reviewed: 5/8/2019)
Pocket Guides
-
2/1/2014
Slide Sets
-
1/15/2014
Primary Care Guidelines
-
11/13/2013 (reviewed: 5/17/2019)
Manuals
-
11/1/2013
Articles: 8
-
Immediate ART Initiation: Guide for Clinicians
Immediate antiretroviral therapy (ART) refers to starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first clinic visit (and even on the same day the HIV diagnosis is made). This strategy also is known as "rapid ART," "same-day ART," and "treatment...
-
AETCs at the 2018 Ryan White Conference
The AETC Program will be well represented at the 2018 National Ryan White Conference on HIV Care & Treatment. Additionally, the AETC National Coordinating Resource Center will be exhibiting an array of AETC Program developed resources and promotional items at Booth #12 in...
-
Ibalizumab Approved for Persons with Multidrug Resistant HIV
Ibalizumab (TNX-355), an entry inhibitor, has been approved by the FDA for use in persons with an extensive ARV treatment history and multidrug resistant HIV who are on a failing ARV regimen. Ibalizumab (trade name: Trogarzo) is a monoclonal antibody that binds the CD4 receptor and blocks HIV...
-
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
CROI 2017: Failure of Dolutegravir Monotherapy
Leading up to this year, some researchers and clinicians had optimistically viewed dolutegravir an invincible ARV, a drug so mighty that it was unlikely to fail, and even more unlikely to be victim to emergent resistance mutations. Two presentations at CROI demonstrated the...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
Switching from TDF/FTC to TAF/FTC
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...
-
Sep 142020 STD Prevention ConferenceEvent type: Conferences & Events